Analytical Method Development and Validation of Ticagrelor from Bulk and Formulation
By: Gupta, Anand
.
Contributor(s): Jadhav, Vaishali.
Publisher: Raipur Asian Pharma Press 2019Edition: Vol.9(3), Sep.Description: 141-146p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Asian journal of pharmaceutical researchSummary: Ticagrelor is a Platelet Aggregation Inhibitor which is white to off-white, highly crystalline and non-hygroscopic powder, having High Solubility and Low Permeability. A Simple, Rapid, Selective, Precise and Accurate UV and HPLC Method have been developed for the Estimation of Ticagrelor in bulk drugs and its Tablet dosage form. The max was found to be ?max 255 nm. As per the solution stability experiments, this drug was stable in the solvent composition of ACN:Methanol (85:15 v/v) and hence used as a diluent for sample preparation. The developed method was optimized to get reproducible results with minimum run time. The Stationary Phase was C18 (250 x 4.6 mm i.d., 5µ) Mobile Phase was ACN:Methanol (85:15 v/v), Flow rate 1.0 ml/min, Injection volume 10 µl, PDA detection at ?max 255nm and Run time 7 min. It provides a linear response over the Conc. Range of 5-25 µg/ml with Correlation Co-efficient of 0.999 and LOD and LOQ was found to be 0.20 µg/ml and 0.61 µg/ml respectively. %Recovery was found to be 99.06, 99.77, and 100.99% for the levels of 80, 100, and 120% respectively. Both the Method was found to be Robust with better accuracy and Precision having % RSD value less than 2.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2020667 |
Ticagrelor is a Platelet Aggregation Inhibitor which is white to off-white, highly crystalline and non-hygroscopic powder, having High Solubility and Low Permeability. A Simple, Rapid, Selective, Precise and Accurate UV and HPLC Method have been developed for the Estimation of Ticagrelor in bulk drugs and its Tablet dosage form. The max was found to be ?max 255 nm. As per the solution stability experiments, this drug was stable in the solvent composition of ACN:Methanol (85:15 v/v) and hence used as a diluent for sample preparation. The developed method was optimized to get reproducible results with minimum run time. The Stationary Phase was C18 (250 x 4.6 mm i.d., 5µ) Mobile Phase was ACN:Methanol (85:15 v/v), Flow rate 1.0 ml/min, Injection volume 10 µl, PDA detection at ?max 255nm and Run time 7 min. It provides a linear response over the Conc. Range of 5-25 µg/ml with Correlation Co-efficient of 0.999 and LOD and LOQ was found to be 0.20 µg/ml and 0.61 µg/ml respectively. %Recovery was found to be 99.06, 99.77, and 100.99% for the levels of 80, 100, and 120% respectively. Both the Method was found to be Robust with better accuracy and Precision having % RSD value less than 2.
Click on an image to view it in the image viewer
There are no comments for this item.